Indegene's valuation reaches $700 mn; raises $200 mn from Carlyle, Brighton

Given the wider adoption of digital initiatives within the healthcare industry, Indegene plans to use the funds to accelerate its M&A (merger and acquisition) and global expansion plans

Private equity firm Carlyle Group and Brighton Park Capital are investing $200 million in Indegene, the Bengaluru-headquartered enterprise healthtech solutions provider, for a minority stake. The transaction, which is subject to customary regulatory approvals, consists of a secondary sale from existing shareholders of Indegene and a primary investment into the company. The firm did not reveal the valuation after this funding round. According to the sources, the valuation of Indegene has increased to about $700 million.

Rising competition in the global pharmaceutical market is shifting business models and driving multi-year digital transformation programmes. Decisions are increasingly data-driven and leading healthcare